11β-hydroxylase deficiency differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 17: Line 17:
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Decreased
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Decreased
|-
|-
|[[21-hydroxylase deficiency|Classic type of 21-hydroxylase deficiency]]
![[21-hydroxylase deficiency|Classic type of 21-hydroxylase deficiency]]
|
|
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
Line 33: Line 33:
* [[Hypotension]] and [[hyperkalemia]]
* [[Hypotension]] and [[hyperkalemia]]
|-
|-
|[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
![[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
|
|
* [[Deoxycorticosterone]]
* [[Deoxycorticosterone]]
Line 47: Line 47:
* [[Virilization]]
* [[Virilization]]
|-
|-
|[[17 alpha-hydroxylase deficiency|17-α hydroxylase deficiency]]
![[17 alpha-hydroxylase deficiency|17-α hydroxylase deficiency]]
|
|
* [[Deoxycorticosterone]]
* [[Deoxycorticosterone]]
Line 65: Line 65:
* Minimal [[body hair]]
* Minimal [[body hair]]
|-
|-
|[[3 beta-hydroxysteroid dehydrogenase deficiency]]
![[3 beta-hydroxysteroid dehydrogenase deficiency]]
|
|
* [[Dehydroepiandrosterone]]
* [[Dehydroepiandrosterone]]
Line 77: Line 77:
* 46-XY infants often show [[undervirilization]], due to a block in [[testosterone]] synthesis
* 46-XY infants often show [[undervirilization]], due to a block in [[testosterone]] synthesis
|-
|-
| Gestational [[hyperandrogenism]]
! Gestational [[hyperandrogenism]]
| colspan="2" |
| colspan="2" |
* Maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]]) are high  
* Maternal serum [[androgen]] concentrations (usually [[testosterone]] and [[androstenedione]]) are high  
Line 96: Line 96:
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Important clinical findings
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Important clinical findings
|-
|-
|Non-classic type of [[21-hydroxylase deficiency]]
!Non-classic type of [[21-hydroxylase deficiency]]
|Increased:
|Increased:
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
* [[17-Hydroxyprogesterone|17-hydroxyprogesterone]]
Line 107: Line 107:
* [[Virilization]] in females
* [[Virilization]] in females
|-
|-
|[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
![[11β-hydroxylase deficiency|11-β hydroxylase deficiency]]
|Increased:
|Increased:
* DOC
* DOC
Line 121: Line 121:
* [[Virilization]]
* [[Virilization]]
|-
|-
|[[3 beta-hydroxysteroid dehydrogenase deficiency]]
![[3 beta-hydroxysteroid dehydrogenase deficiency]]
|Increased:
|Increased:
* [[DHEA]]
* [[DHEA]]
Line 137: Line 137:
* [[Undervirilization]] of genetically male infants, making it the only form of [[CAH]] which can cause [[ambiguous genitalia]] in both genetic sexes.  
* [[Undervirilization]] of genetically male infants, making it the only form of [[CAH]] which can cause [[ambiguous genitalia]] in both genetic sexes.  
|-
|-
|[[Polycystic ovary syndrome ]]
![[Polycystic ovary syndrome ]]
|
|
* High [[DHEAS]] and [[androstenedione]] levels
* High [[DHEAS]] and [[androstenedione]] levels
Line 148: Line 148:
* No evidence another diagnosis  
* No evidence another diagnosis  
|-
|-
|[[Adrenal tumors]]
![[Adrenal tumors]]
|
|
* Variable levels depends on [[tumor]] type
* Variable levels depends on [[tumor]] type
Line 157: Line 157:
* Rapidly progressive symptoms
* Rapidly progressive symptoms
|-
|-
|Ovarian [[virilizing]] tumor
!Ovarian [[virilizing]] tumor
|
|
* Variable levels depends on [[tumor]] type
* Variable levels depends on [[tumor]] type
Line 166: Line 166:
* Rapidly progressive symptoms
* Rapidly progressive symptoms
|-
|-
|[[Cushing's syndrome]]
![[Cushing's syndrome]]
|
|
* Increase [[cortisol]] & metabolites
* Increase [[cortisol]] & metabolites
Line 175: Line 175:
* [[Cushingoid appearance]]
* [[Cushingoid appearance]]
|-
|-
|[[Hyperprolactinemia]]
![[Hyperprolactinemia]]
|
|
* Normal levels of most of [[steroids]]
* Normal levels of most of [[steroids]]
Line 199: Line 199:
|-
|-
| rowspan="9" |Endogenous causes
| rowspan="9" |Endogenous causes
|[[17 alpha-hydroxylase deficiency]]
![[17 alpha-hydroxylase deficiency]]
|Mutations in the [[CYP17A1]] gene
|Mutations in the [[CYP17A1]] gene
|
|
Line 216: Line 216:
| rowspan="2" |[[Corticosteroids]]
| rowspan="2" |[[Corticosteroids]]
|-
|-
|[[11β-hydroxylase deficiency]]
![[11β-hydroxylase deficiency]]
|Mutations in the [[CYP11B1]] gene
|Mutations in the [[CYP11B1]] gene
|
|
Line 225: Line 225:
|[[Cortisol]] ↓
|[[Cortisol]] ↓
|-
|-
|Apparent mineralocorticoid excess syndrome (AME)
!Apparent mineralocorticoid excess syndrome (AME)
|Genetic or acquired defect of 11-HSD gene  
|Genetic or acquired defect of 11-HSD gene  
* [[Cortisone]] decreases and [[cortisol]] accumulates and binds to [[aldosterone]] receptors  
* [[Cortisone]] decreases and [[cortisol]] accumulates and binds to [[aldosterone]] receptors  
Line 238: Line 238:
|[[Dexamethasone]] and/or [[mineralocorticoid]] blockers
|[[Dexamethasone]] and/or [[mineralocorticoid]] blockers
|-
|-
|[[Liddle's syndrome|Liddle’s syndrome]] (Pseudohyperaldosteronism type 1)
![[Liddle's syndrome|Liddle’s syndrome]] (Pseudohyperaldosteronism type 1)
|Mutation of the epithelial [[sodium]] channels ([[ENaC]]) [[gene]] in the distal [[renal tubules]]
|Mutation of the epithelial [[sodium]] channels ([[ENaC]]) [[gene]] in the distal [[renal tubules]]
|
|
Line 250: Line 250:
|[[Amiloride]] or [[triamterene]]  
|[[Amiloride]] or [[triamterene]]  
|-
|-
|[[Cushing’s syndrome]]
![[Cushing’s syndrome]]
|
|
* Due to excess [[cortisol]] which saturates 11-HSD2 activity
* Due to excess [[cortisol]] which saturates 11-HSD2 activity
Line 272: Line 272:
* Adrenalectomy
* Adrenalectomy
|-
|-
|Insensitivity to [[glucocorticoids]] (Chrousos syndrome)
!Insensitivity to [[glucocorticoids]] (Chrousos syndrome)
|Mutations in [[glucocorticoid receptor]] (GR) gene
|Mutations in [[glucocorticoid receptor]] (GR) gene
|
|
Line 284: Line 284:
|[[Dexamethasone]]
|[[Dexamethasone]]
|-
|-
|[[Cortisol]]-secreting adrenocortical [[carcinoma]]
![[Cortisol]]-secreting adrenocortical [[carcinoma]]
|Multifactorial
|Multifactorial
|
|
Line 301: Line 301:
|[[Surgery]]
|[[Surgery]]
|-
|-
|Geller’s syndrome
!Geller’s syndrome
|[[Mutation]] of [[mineralocorticoid]] (MR) receptor that alters its specificity and allows [[progesterone]] to bind MR
|[[Mutation]] of [[mineralocorticoid]] (MR) receptor that alters its specificity and allows [[progesterone]] to bind MR
|Severe [[hypertension]] particularly during [[pregnancy]]
|Severe [[hypertension]] particularly during [[pregnancy]]
Line 310: Line 310:
|[[mineralocorticoid]] blockers
|[[mineralocorticoid]] blockers
|-
|-
|Gordon’s syndrome (Pseudohypoaldosteronism type 2)
!Gordon’s syndrome (Pseudohypoaldosteronism type 2)
|Mutations of at least four genes have been identified, including WNK1 and WNK4
|Mutations of at least four genes have been identified, including WNK1 and WNK4
|
|
Line 325: Line 325:
|-
|-
| rowspan="4" |Exogenous causes
| rowspan="4" |Exogenous causes
|Corticosteroids with mineralocorticoid activity
!Corticosteroids with mineralocorticoid activity
|[[Fludrocortisone]] or fluoroprednisolone can mimic the action of [[aldosterone]]
|[[Fludrocortisone]] or fluoroprednisolone can mimic the action of [[aldosterone]]
|
|
Line 337: Line 337:
|Change the treatment
|Change the treatment
|-
|-
|Licorice ingestion
!Licorice ingestion
|[[Glycyrrhetinic acid]] that binds [[mineralocorticoid]] receptor and blocks 11-HSD2 at the level of classical target tissues of [[aldosterone]]
|[[Glycyrrhetinic acid]] that binds [[mineralocorticoid]] receptor and blocks 11-HSD2 at the level of classical target tissues of [[aldosterone]]
|
|
Line 349: Line 349:
|Discontinue licorice
|Discontinue licorice
|-
|-
|Grapefruit
!Grapefruit
|High assumption of naringenin, a component of grapefruit, can also block 11-HSD
|High assumption of naringenin, a component of grapefruit, can also block 11-HSD
|
|
Line 359: Line 359:
|Discontinue grapefruit
|Discontinue grapefruit
|-
|-
|[[Estrogens]]
![[Estrogens]]
|[[Estrogens]] can retain [[sodium]] and water by different mechanisms, causing:
|[[Estrogens]] can retain [[sodium]] and water by different mechanisms, causing:
* Increased blood pressure values and suppressing the [[renin]] [[aldosterone]] system, on the other side inducing secondary hyperaldosteronism due to the stimulation of the synthesis of [[angiotensinogen]]
* Increased blood pressure values and suppressing the [[renin]] [[aldosterone]] system, on the other side inducing secondary hyperaldosteronism due to the stimulation of the synthesis of [[angiotensinogen]]

Revision as of 14:18, 3 October 2017

Congenital adrenal hyperplasia main page

11β-hydroxylase deficiency Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating 11β-hydroxylase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

11β-hydroxylase deficiency differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 11β-hydroxylase deficiency differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 11β-hydroxylase deficiency differential diagnosis

CDC on 11β-hydroxylase deficiency differential diagnosis

11β-hydroxylase deficiency differential diagnosis in the news

Blogs on 11β-hydroxylase deficiency differential diagnosis

Directions to Hospitals Treating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency

Risk calculators and risk factors for 11β-hydroxylase deficiency differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]

Overview

11β-hydroxylase deficiency must be differentiated from diseases that cause ambiguous genitalia such as 21-hydroxylase deficiency, 17 alpha-hydroxylase deficiency, 3 beta-hydroxysteroid dehydrogenase deficiency and Gestational hyperandrogenism.

Differentiating 11β-hydroxylase deficiency from other diseases

11-hydroxylase deficiency must be differentiated from diseases that cause ambiguous genitalia:[1][2]

Disease name Steroid status Important clinical findings
Increased Decreased
Classic type of 21-hydroxylase deficiency
11-β hydroxylase deficiency
17-α hydroxylase deficiency
3 beta-hydroxysteroid dehydrogenase deficiency
Gestational hyperandrogenism

11β-hydroxylase deficiency must be differentiated from diseases that cause virilization and hirsutism in female:[3][2][4]

Disease name Steroid status Other laboratory Important clinical findings
Non-classic type of 21-hydroxylase deficiency Increased:
  • No symptoms in infancy and male
11-β hydroxylase deficiency Increased:

Decreased:

3 beta-hydroxysteroid dehydrogenase deficiency Increased:

Decreased:

Polycystic ovary syndrome
Adrenal tumors
  • Variable levels depends on tumor type
  • Older age
  • Rapidly progressive symptoms
Ovarian virilizing tumor
  • Variable levels depends on tumor type
  • Older age
  • Rapidly progressive symptoms
Cushing's syndrome
Hyperprolactinemia

11β-hydroxylase deficiency can cause low reninemic hypertension and should be differentiate from other causes of pseudohyperaldosteronism (low renin):

Pseudohyperaldosteronism causes Disease Etiology Clinical features Labratory Treatment
Elevated mineralocorticoid Renin Aldosterone Other
Endogenous causes 17 alpha-hydroxylase deficiency Mutations in the CYP17A1 gene Deoxycorticosterone (DOC) Cortisol Corticosteroids
11β-hydroxylase deficiency Mutations in the CYP11B1 gene Cortisol
Apparent mineralocorticoid excess syndrome (AME) Genetic or acquired defect of 11-HSD gene Cortisol has mineralocorticoid effects Urinary free cortisone ↓↓ Dexamethasone and/or mineralocorticoid blockers
Liddle’s syndrome (Pseudohyperaldosteronism type 1) Mutation of the epithelial sodium channels (ENaC) gene in the distal renal tubules No extra mineralocorticoid presents, and mutations in Na channels mimic aldosterone mechanism Cortisol Amiloride or triamterene
Cushing’s syndrome
  • Due to excess cortisol which saturates 11-HSD2 activity
Rapid weight gain, particularly of the trunk and face with limbs sparing (central obesity) Cortisol has mineralocorticoid effects
  • ↓ if excess cortisol saturates 11-HSD2 enzyme activity
Urinary free cortisol markedly ↑↑
  • Adrenalectomy
Insensitivity to glucocorticoids (Chrousos syndrome) Mutations in glucocorticoid receptor (GR) gene Deoxycorticosterone (DOC) Cortisol Dexamethasone
Cortisol-secreting adrenocortical carcinoma Multifactorial

Rapid weight gain, particularly of the trunk and face with limbs sparing (central obesity)

Cortisol has mineralocorticoid effects
  • ↓ if excess cortisol saturates 11-HSD2 enzyme activity
Urinary free cortisol markedly ↑↑ Surgery
Geller’s syndrome Mutation of mineralocorticoid (MR) receptor that alters its specificity and allows progesterone to bind MR Severe hypertension particularly during pregnancy Progesterone has mineralocorticoid effects - mineralocorticoid blockers
Gordon’s syndrome (Pseudohypoaldosteronism type 2) Mutations of at least four genes have been identified, including WNK1 and WNK4
  • Normal renal function
No excess mineralocorticoid; an increased activity of the thiazide-sensitive Na–Cl co-transporter in the distal tubule Normal Hyperkalemia Thiazide diuretics and/or dietary sodium restriction
Exogenous causes Corticosteroids with mineralocorticoid activity Fludrocortisone or fluoroprednisolone can mimic the action of aldosterone Medications such as fludrocortisone - Change the treatment
Licorice ingestion Glycyrrhetinic acid that binds mineralocorticoid receptor and blocks 11-HSD2 at the level of classical target tissues of aldosterone - Urinary free cortisol Moderate ↑ Discontinue licorice
Grapefruit High assumption of naringenin, a component of grapefruit, can also block 11-HSD - - Discontinue grapefruit
Estrogens Estrogens can retain sodium and water by different mechanisms, causing:
  • Increased blood pressure values and suppressing the renin aldosterone system, on the other side inducing secondary hyperaldosteronism due to the stimulation of the synthesis of angiotensinogen
- - Discontinue estrogens

References

  1. Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT (2007). "Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development". Best Pract. Res. Clin. Endocrinol. Metab. 21 (3): 351–65. doi:10.1016/j.beem.2007.06.003. PMID 17875484.
  2. 2.0 2.1 White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.
  3. Hohl A, Ronsoni MF, Oliveira M (2014). "Hirsutism: diagnosis and treatment". Arq Bras Endocrinol Metabol. 58 (2): 97–107. PMID 24830586. Vancouver style error: initials (help)
  4. Melmed, Shlomo (2016). Williams textbook of endocrinology. Philadelphia, PA: Elsevier. ISBN 978-0323297387.=